) colorectal cancer who have received prior treatment with a fluoropyrimidine (5-FU or capecitabine) and oxaliplatin or who have experienced a recurrence within 12 months of adjuvant therapy with a regimen that included oxaliplatin. For study purposes, a cycle
Search Results
unresectable) colorectal cancer who have received prior treatment with a fluoropyrimidine (5-FU or capecitabine) and oxaliplatin or who have experienced a recurrence within 12 months of adjuvant therapy with a regimen that included oxaliplatin. For study
Al B. Benson III, Alan P. Venook, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Steven Hunt, Ahmed Kamel, Lucille A. Leong, Edward Lin, Wells Messersmith, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Kristina M. Gregory, and Deborah A. Freedman-Cass
, because the goal is not specifically the eradication of micrometastatic disease, but rather the obtaining of optimal size regression of the visible metastases. An important point to keep in mind is that irinotecan- and oxaliplatin-based chemotherapeutic
Clayton A. Smith and Lisa A. Kachnic
III rectal cancer were randomized in a 2 x 2 design to either continuous infusion 5-FU or capecitabine with or without oxaliplatin given concurrently with long-course RT. 24 , 25 No differences were seen in rates of 5-year OS (79.9% vs 80.8%; P =.61
Maxwell T. Vergo and Al B. Benson III
chemotherapy (5-fluorouracil/leucovorin [5-FU/LV] or capecitabine alone in T3,N0 disease without high-risk features; 5-FU/LV or capecitabine or 5-FU/LV plus oxaliplatin or capecitabine plus oxaliplatin in T3,N0 with high-risk features or T4,N0 disease) after
Kristen Keon Ciombor and Tanios Bekaii-Saab
Standards of Care in mCRC For many years, fluoropyrimidines in combination with leucovorin were the sole efficacious agents for the treatment of mCRC. 2 , 3 With the advent of oxaliplatin 4 and irinotecan, 5 , 6 however, treatment of mCRC with various
Al B. Benson III, Alan P. Venook, Mahmoud M. Al-Hawary, Lynette Cederquist, Yi-Jen Chen, Kristen K. Ciombor, Stacey Cohen, Harry S. Cooper, Dustin Deming, Paul F. Engstrom, Ignacio Garrido-Laguna, Jean L. Grem, Axel Grothey, Howard S. Hochster, Sarah Hoffe, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Smitha Krishnamurthi, Wells A. Messersmith, Jeffrey Meyerhardt, Eric D. Miller, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Evan Wuthrick, Kristina M. Gregory, and Deborah A. Freedman-Cass
, randomized controlled trials have shown that the addition of oxaliplatin to these adjuvant regimens benefits some patients. 15 – 19 However, adjuvant treatment, especially with regimens containing oxaliplatin, is associated with considerable toxicity
John G. Phillips, Theodore S. Hong, and David P. Ryan
concurrent chemotherapies: continuous-infusion 5-FU; continuous-infusion 5-FU with oxaliplatin; capecitabine; or capecitabine and oxaliplatin. Preliminary data thus far show no difference in pCR, sphincter-sparing surgery, and surgical downstaging. 25 Three
Nancy Kemeny
survival with this approach. In one study using HAI FUDR/Dex plus systemic oxaliplatin and irinotecan, the response rate in second-line therapy was 88% with a 35-month median survival. 8 When compared with second-line systemic therapy, which has a low
Al B. Benson III
Guidelines in Oncology (NCCN Guidelines) for Colorectal Cancer appear. Treatment options include 5-FU, leucovorin, and irinotecan, with limited sequential therapy options, and shift median survival to about 1 year. Ten years ago, oxaliplatin and 5-FU
